Immunis

Irvine, United States

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

$25.0M raised

Jul 2024

Series A

Top Investors

Remiges VenturesBold Capital PartnersIronwood VenturesLifespan Vision VenturesJLS Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Immunis raised?

Immunis has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in July 2024.

Who are Immunis's investors?

Immunis's investors include Remiges Ventures, Bold Capital Partners, Ironwood Ventures, Lifespan Vision Ventures, JLS Fund.

Where is Immunis headquartered?

Immunis is headquartered in Irvine, United States.

What does Immunis do?

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

What stage is Immunis at?

Immunis is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 1, 2024.

MLA

"Immunis — Funding & Investors." VCBacked, July 1, 2024, https://www.vcbacked.co/company/immunis. Accessed June 17, 2026.

APA

VCBacked. (2024). Immunis — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/immunis

Wikipedia (cite web)

{{cite web |title=Immunis — Funding & Investors |url=https://www.vcbacked.co/company/immunis |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 1, 2024.